A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) and 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in HIV Infections and Pneumococcal Infections, sponsored by Pfizer. Completed at 11 sites in 2 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2014-11-17.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in HIV Infections by Pfizer — none open to participants now, none under way, none of them phase 3. HIV Infections · Pfizer.
Among the 65 studies in HIV Infections by Pfizer, this one is the 8th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2010, is one of 10 in phase 3, and was the 63rd registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →None of the 65 studies in HIV Infections by Pfizer is open now. The open studies under HIV Infections, anywhere →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 303 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 160 across the 28 interventional studies, 476 across the 1 observational. Of the 65 that completed or were terminated, 5 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 65 studies in HIV Infections by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will evaluate the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 6 years of age or older who have not been previously immunized with a pneumococcal vaccine. All subjects will receive 3 doses of 13vPnC and 1 dose of 23-valent pneumococcal polysaccharide vaccine (23vPS), with each dose given approximately 1 month apart.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 doses of 13vPnC and 1 dose of 23vPS, each dose given approximately 1 month apart
Biological: 13-valent Pneumococcal Conjugate Vaccine (13vPnC) · Biological: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) · Procedure: Blood draw
13vPnC; 3 vaccinations given at approximately 1 month intervals at visits 1-3
23vPS; 1 vaccination given at visit 4 (approximately 1 month after visit 3)
Blood draw; 5 blood draws approximately 1 month apart taken prior to vaccination at visits 1-4 and visit 5 (approximately 1 month after visit 4).
1 or 2 blood draws for CD4+ T cell count and HIV viral load at least 6 weeks apart, if subject does not have 2 CD4+ T cell counts and HIV viral load counts within 6 months before visit 1.
Also known as: Screening blood draw(s)
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in All Participants
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.
Time frame: 1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: 1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: 1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric, Adult and All Participants
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.
Time frame: 1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric and Adult Participants
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.
Time frame: 1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Before and 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both the before and after 13vPnC Dose 1 blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose and after 13vPnC Dose 1 blood draws.
Time frame: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Before and 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both the before and after 13vPnC Dose 1 blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose and after 13vPnC Dose 1 blood draws.
Time frame: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 and 1 Month After 23vPS Dose in Pediatric, Adult and All Participants
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both after 13vPnC Dose 3 and after 23vPS Dose blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: 1 month after 13vPnC Dose 3, 1 month after 23vPS Dose
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 3 to 1 Month After 23vPS Dose in Pediatric, Adult and All Participants
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 23vPS Dose were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 3 and 1 month after 23vPS Dose blood draws.
Time frame: 1 month after 13vPnC Dose 3, 1 month after 23vPS Dose
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 and 1 Month After 23vPS Dose in Pediatric, Adult and All Participants
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a mcOPA assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both after 13vPnC Dose 3 and after 23vPS Dose blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: 1 month after 13vPnC Dose 3, 1 month after 23vPS Dose
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From 1 Month After 13vPnC Dose 3 to 1 Month After 23vPS Dose in Pediatric, Adult and All Participants
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 23vPS Dose were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 3 and 1 month after 23vPS Dose blood draws.
Time frame: 1 month after 13vPnC Dose 3, 1 month after 23vPS Dose
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 1
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters (cm) for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged greater than (\>) 12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Report of severe swelling was confirmed as data entry error.
Time frame: Within 14 days after 13vPnC Dose 1
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 2
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 cm for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged \>12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).
Time frame: Within 14 days after 13vPnC Dose 2
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 3
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 cm for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged \>12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).
Time frame: Within 14 days after 13vPnC Dose 3
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 1
Specific systemic events (fever \>=38 degrees Celsius\[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours). All reporting of fever \>40 degrees C except 2 participants and all reporting of severe vomiting, after 13vPnC Dose 1, were confirmed as data entry errors.
Time frame: Within 14 days after 13vPnC Dose 1
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 2
Specific systemic events (fever \>=38 degrees Celsius\[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours). All reporting of fever \>40 degrees C and all reporting of severe vomiting, after 13vPnC Dose 2, were confirmed as data entry errors.
Time frame: Within 14 days after 13vPnC Dose 2
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 3
Specific systemic events (fever \>=38 degrees Celsius\[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours). All reporting of fever \>40 degrees C except 1 participant and all reporting of severe vomiting, after 13vPnC Dose 3, were confirmed as data entry errors.
Time frame: Within 14 days after 13vPnC Dose 3
| Milestone | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) |
|---|---|---|
| Started | 151 | 152 |
| Vaccinated 13vpnc dose 1 | 150 | 151 |
| Vaccinated 13vpnc dose 2 | 145 | 145 |
| Vaccinated 13vpnc dose 3 | 144 | 142 |
| Vaccinated 23vps dose | 143 | 139 |
| Completed | 141 | 138 |
| Not completed | 10 | 14 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Protocol violation | 9 | 4 |
| Withdrew: Withdrawal by subject | 1 | 8 |
| Withdrew: Other | 0 | 1 |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.
| fold rise | 13vPnC, 23vPS (All Participants) |
|---|---|
| Serotype 1 (n = 248) | 1.03 (0.99 to 1.07) |
| Serotype 3 (n = 238) | 1.05 (1.00 to 1.10) |
| Serotype 4 (n = 257) | 1.09 (1.03 to 1.14) |
| Serotype 5 (n = 257) | 1.01 (0.97 to 1.05) |
| Serotype 6A (n = 249) | 1.02 (0.97 to 1.07) |
| Serotype 6B (n = 257) | 1.04 (1.01 to 1.08) |
| Serotype 7F (n = 259) | 1.10 (1.05 to 1.16) |
| Serotype 9V (n = 259) | 1.05 (1.01 to 1.09) |
| Serotype 14 (n = 259) | 1.04 (1.00 to 1.09) |
| Serotype 18C (n = 259) | 0.99 (0.96 to 1.02) |
| Serotype 19A (n = 259) | 0.99 (0.96 to 1.03) |
| Serotype 19F (n = 252) | 1.06 (1.01 to 1.11) |
| Serotype 23F (n = 258) | 1.09 (1.03 to 1.15) |
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| microgram per milliliter (mcg/mL) | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Serotype 1: 13vPnC Dose 2 (n = 120, 128, 248) | 3.88 (3.30 to 4.57) | 3.95 (3.23 to 4.85) | 3.92 (3.44 to 4.46) |
| Serotype 1: 13vPnC Dose 3 (n = 120, 128, 248) | 4.14 (3.56 to 4.83) | 3.92 (3.21 to 4.79) | 4.03 (3.55 to 4.57) |
| Serotype 3: 13vPnC Dose 2 (n = 118, 120, 238) | 1.47 (1.25 to 1.74) | 0.97 (0.81 to 1.16) | 1.19 (1.05 to 1.35) |
| Serotype 3: 13vPnC Dose 3 (n = 118, 120, 238) | 1.49 (1.26 to 1.76) | 1.06 (0.88 to 1.27) | 1.25 (1.11 to 1.42) |
| Serotype 4: 13vPnC Dose 2 (n = 127, 130, 257) | 3.06 (2.54 to 3.69) | 2.97 (2.40 to 3.67) | 3.01 (2.62 to 3.47) |
| Serotype 4: 13vPnC Dose 3 (n = 127, 130, 257) | 3.36 (2.84 to 3.97) | 3.19 (2.59 to 3.91) | 3.27 (2.87 to 3.73) |
| Serotype 5: 13vPnC Dose 2 (n = 126, 131, 257) | 4.52 (3.78 to 5.39) | 5.77 (4.83 to 6.89) | 5.12 (4.51 to 5.80) |
| Serotype 5: 13vPnC Dose 3 (n = 126, 131, 257) | 4.84 (4.12 to 5.70) | 5.53 (4.63 to 6.61) | 5.18 (4.60 to 5.85) |
| Serotype 6A: 13vPnC Dose 2 (n = 119, 130, 249) | 7.66 (6.46 to 9.08) | 7.03 (5.71 to 8.67) | 7.33 (6.40 to 8.39) |
| Serotype 6A: 13vPnC Dose 3 (n = 119, 130, 249) | 7.97 (6.81 to 9.33) | 7.04 (5.74 to 8.64) | 7.47 (6.56 to 8.51) |
| Serotype 6B: 13vPnC Dose 2 (n = 127, 130, 257) | 11.43 (9.45 to 13.84) | 7.93 (6.51 to 9.65) | 9.50 (8.28 to 10.91) |
| Serotype 6B: 13vPnC Dose 3 (n = 127, 130, 257) | 11.94 (10.01 to 14.24) | 8.28 (6.78 to 10.11) | 9.92 (8.67 to 11.35) |
| Serotype 7F: 13vPnC Dose 2 (n = 128, 131, 259) | 4.25 (3.67 to 4.92) | 5.78 (4.81 to 6.95) | 4.96 (4.41 to 5.59) |
| Serotype 7F: 13vPnC Dose 3 (n = 128, 131, 259) | 5.05 (4.38 to 5.82) | 5.90 (4.95 to 7.04) | 5.46 (4.88 to 6.12) |
| Serotype 9V: 13vPnC Dose 2 (n = 128, 131, 259) | 4.81 (4.18 to 5.54) | 5.14 (4.27 to 6.19) | 4.98 (4.43 to 5.59) |
| Serotype 9V: 13vPnC Dose 3 (n = 128, 131, 259) | 4.98 (4.35 to 5.70) | 5.48 (4.59 to 6.55) | 5.23 (4.67 to 5.84) |
| Serotype 14: 13vPnC Dose 2 (n = 128, 131, 259) | 11.60 (8.76 to 15.35) | 15.14 (11.64 to 19.71) | 13.27 (10.96 to 16.08) |
| Serotype 14: 13vPnC Dose 3 (n = 128, 131, 259) | 12.62 (9.75 to 16.33) | 15.13 (11.80 to 19.40) | 13.83 (11.57 to 16.53) |
| Serotype 18C: 13vPnC Dose 2 (n = 128, 131, 259) | 3.79 (3.12 to 4.60) | 5.33 (4.34 to 6.54) | 4.50 (3.91 to 5.19) |
| Serotype 18C: 13vPnC Dose 3 (n = 128, 131, 259) | 3.83 (3.19 to 4.60) | 5.18 (4.27 to 6.28) | 4.46 (3.90 to 5.10) |
| Serotype 19A: 13vPnC Dose 2 (n = 128, 131, 259) | 14.38 (12.20 to 16.96) | 13.19 (11.06 to 15.75) | 13.77 (12.21 to 15.53) |
| Serotype 19A: 13vPnC Dose 3 (n = 128, 131, 259) | 14.19 (12.17 to 16.54) | 13.18 (11.11 to 15.62) | 13.67 (12.20 to 15.32) |
| Serotype 19F: 13vPnC Dose 2 (n = 124, 128, 252) | 5.78 (4.63 to 7.21) | 5.34 (4.17 to 6.84) | 5.55 (4.71 to 6.55) |
| Serotype 19F: 13vPnC Dose 3 (n = 124, 128, 252) | 6.09 (4.98 to 7.44) | 5.67 (4.47 to 7.18) | 5.87 (5.03 to 6.85) |
| Serotype 23F: 13vPnC Dose 2 (n = 127, 131, 258) | 6.45 (5.30 to 7.85) | 6.10 (4.86 to 7.66) | 6.27 (5.40 to 7.28) |
| Serotype 23F: 13vPnC Dose 3 (n = 127, 131, 258) | 6.64 (5.55 to 7.94) | 7.06 (5.65 to 8.82) | 6.85 (5.94 to 7.90) |
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| titers | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Serotype 1: 13vPnC Dose 2 (n = 126, 127, 253) | 51 (37.2 to 70.0) | 54 (38.7 to 74.2) | 52 (41.8 to 65.5) |
| Serotype 1: 13vPnC Dose 3 (n = 126, 127, 253) | 69 (51.6 to 91.4) | 69 (51.3 to 92.0) | 69 (56.1 to 84.1) |
| Serotype 3: 13vPnC Dose 2 (n = 127, 129, 256) | 81 (64.1 to 102.0) | 48 (37.9 to 61.5) | 62 (52.6 to 73.9) |
| Serotype 3: 13vPnC Dose 3 (n = 127, 129, 256) | 114 (94.5 to 137.8) | 79 (62.1 to 99.9) | 95 (81.3 to 110.3) |
| Serotype 4: 13vPnC Dose 2 (n = 117, 126, 243) | 2509 (1922.3 to 3274.2) | 1620 (1211.2 to 2167.4) | 2000 (1639.8 to 2439.1) |
| Serotype 4: 13vPnC Dose 3 (n = 117, 126, 243) | 3246 (2697.1 to 3906.3) | 1944 (1465.3 to 2579.7) | 2488 (2092.1 to 2959.8) |
| Serotype 5: 13vPnC Dose 2 (n = 122, 124, 246) | 159 (109.2 to 232.2) | 104 (69.1 to 156.9) | 129 (97.3 to 169.7) |
| Serotype 5: 13vPnC Dose 3 (n = 122, 124, 246) | 267 (191.3 to 371.5) | 142 (97.5 to 206.7) | 194 (150.8 to 249.7) |
| Serotype 6A: 13vPnC Dose 2 (n = 125, 124, 249) | 5560 (4378.4 to 7060.9) | 2425 (1790.7 to 3284.5) | 3678 (3016.2 to 4485.6) |
| Serotype 6A: 13vPnC Dose 3 (n = 125, 124, 249) | 7758 (6314.2 to 9531.2) | 3239 (2488.5 to 4215.9) | 5022 (4216.8 to 5979.9) |
| Serotype 6B: 13vPnC Dose 2 (n = 121, 128, 249) | 5449 (4365.1 to 6801.1) | 2724 (2004.8 to 3701.0) | 3815 (3140.9 to 4634.1) |
| Serotype 6B: 13vPnC Dose 3 (n = 121, 128, 249) | 7151 (5828.2 to 8773.9) | 3723 (2771.1 to 5002.5) | 5113 (4250.1 to 6150.5) |
| Serotype 7F: 13vPnC Dose 2 (n = 125, 127, 252) | 3494 (2772.8 to 4403.3) | 2255 (1739.6 to 2923.6) | 2802 (2352.6 to 3338.0) |
| Serotype 7F: 13vPnC Dose 3 (n = 125, 127, 252) | 4638 (3889.7 to 5529.4) | 2702 (2130.3 to 3428.2) | 3533 (3037.4 to 4108.5) |
| Serotype 9V: 13vPnC Dose 2 (n = 118, 127, 245) | 3339 (2461.4 to 4530.3) | 1432 (998.6 to 2054.9) | 2153 (1690.3 to 2743.3) |
| Serotype 9V: 13vPnC Dose 3 (n = 118, 127, 245) | 4714 (3731.5 to 5955.4) | 2004 (1416.5 to 2836.1) | 3026 (2434.3 to 3761.4) |
| Serotype 14: 13vPnC Dose 2 (n = 117, 127, 244) | 3704 (2906.5 to 4719.5) | 1342 (1010.1 to 1782.1) | 2183 (1792.2 to 2659.6) |
| Serotype 14: 13vPnC Dose 3 (n = 117, 127, 244) | 3963 (3195.8 to 4914.2) | 1480 (1150.3 to 1903.9) | 2373 (1988.4 to 2832.8) |
| Serotype 18C: 13vPnC Dose 2 (n = 117, 121, 238) | 4635 (3609.7 to 5951.8) | 1349 (947.0 to 1921.5) | 2475 (1965.7 to 3115.4) |
| Serotype 18C: 13vPnC Dose 3 (n = 117, 121, 238) | 5579 (4423.7 to 7036.9) | 1787 (1272.8 to 2508.5) | 3127 (2515.2 to 3888.6) |
| Serotype 19A: 13vPnC Dose 2 (n = 125, 127, 252) | 684 (519.2 to 902.1) | 458 (332.5 to 631.2) | 559 (452.3 to 690.9) |
| Serotype 19A: 13vPnC Dose 3 (n = 125, 127, 252) | 1002 (814.5 to 1232.3) | 613 (465.6 to 806.4) | 782 (657.2 to 930.5) |
| Serotype 19F: 13vPnC Dose 2 (n = 122, 118, 240) | 717 (495.6 to 1036.7) | 315 (196.7 to 506.0) | 479 (354.4 to 646.9) |
| Serotype 19F: 13vPnC Dose 3 (n = 122, 118, 240) | 1152 (864.2 to 1535.0) | 597 (397.9 to 897.1) | 834 (650.1 to 1070.2) |
| Serotype 23F: 13vPnC Dose 2 (n = 120, 126, 246) | 1477 (1086.2 to 2008.2) | 409 (271.9 to 614.0) | 765 (585.2 to 999.4) |
| Serotype 23F: 13vPnC Dose 3 (n = 120, 126, 246) | 2327 (1844.2 to 2935.9) | 671 (449.8 to 1000.3) | 1231 (963.0 to 1572.5) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.
| fold rise | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Serotype 1 (n = 126, 127, 253) | 1.3 (1.13 to 1.61) | 1.3 (1.09 to 1.51) | 1.3 (1.16 to 1.48) |
| Serotype 3 (n = 127, 129, 256) | 1.4 (1.25 to 1.59) | 1.6 (1.45 to 1.83) | 1.5 (1.40 to 1.65) |
| Serotype 4 (n = 117, 126, 243) | 1.3 (1.10 to 1.52) | 1.2 (1.07 to 1.34) | 1.2 (1.13 to 1.37) |
| Serotype 5 (n = 122, 124, 246) | 1.7 (1.36 to 2.06) | 1.4 (1.17 to 1.59) | 1.5 (1.33 to 1.72) |
| Serotype 6A (n = 125, 124, 249) | 1.4 (1.22 to 1.60) | 1.3 (1.15 to 1.55) | 1.4 (1.23 to 1.51) |
| Serotype 6B (n = 121, 128, 249) | 1.3 (1.18 to 1.46) | 1.4 (1.20 to 1.56) | 1.3 (1.23 to 1.46) |
| Serotype 7F (n = 125, 127, 252) | 1.3 (1.15 to 1.53) | 1.2 (1.03 to 1.40) | 1.3 (1.14 to 1.40) |
| Serotype 9V (n = 118, 127, 245) | 1.4 (1.16 to 1.72) | 1.4 (1.18 to 1.65) | 1.4 (1.24 to 1.60) |
| Serotype 14 (n = 117, 127, 244) | 1.1 (0.95 to 1.20) | 1.1 (0.98 to 1.24) | 1.1 (1.00 to 1.18) |
| Serotype 18C (n = 117, 121, 238) | 1.2 (1.10 to 1.32) | 1.3 (1.08 to 1.63) | 1.3 (1.13 to 1.42) |
| Serotype 19A (n = 125, 127, 252) | 1.5 (1.27 to 1.68) | 1.3 (1.18 to 1.52) | 1.4 (1.27 to 1.54) |
| Serotype 19F (n = 122, 118, 240) | 1.6 (1.31 to 1.97) | 1.9 (1.45 to 2.48) | 1.7 (1.48 to 2.06) |
| Serotype 23F (n = 120, 126, 246) | 1.6 (1.31 to 1.90) | 1.6 (1.34 to 2.02) | 1.6 (1.40 to 1.85) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.
| fold rise | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) |
|---|---|---|
| Serotype 1 (n = 120, 128) | 1.07 (1.01 to 1.13) | 0.99 (0.93 to 1.06) |
| Serotype 3 (n = 118, 120) | 1.01 (0.95 to 1.08) | 1.09 (1.02 to 1.16) |
| Serotype 4 (n = 127, 130) | 1.10 (1.02 to 1.18) | 1.07 (1.00 to 1.16) |
| Serotype 5 (n = 126, 131) | 1.07 (1.01 to 1.14) | 0.96 (0.91 to 1.01) |
| Serotype 6A (n = 119, 130) | 1.04 (0.96 to 1.12) | 1.00 (0.95 to 1.06) |
| Serotype 6B (n = 127, 130) | 1.04 (0.99 to 1.10) | 1.04 (0.99 to 1.11) |
| Serotype 7F (n = 128, 131) | 1.19 (1.12 to 1.27) | 1.02 (0.95 to 1.10) |
| Serotype 9V (n = 128, 131) | 1.03 (0.98 to 1.09) | 1.07 (1.02 to 1.12) |
| Serotype 14 (n = 128, 131) | 1.09 (1.02 to 1.16) | 1.00 (0.95 to 1.05) |
| Serotype 18C (n = 128, 131) | 1.01 (0.96 to 1.07) | 0.97 (0.93 to 1.01) |
| Serotype 19A (n = 128, 131) | 0.99 (0.93 to 1.04) | 1.00 (0.96 to 1.04) |
| Serotype 19F (n = 124, 128) | 1.05 (0.98 to 1.13) | 1.06 (0.99 to 1.14) |
| Serotype 23F (n = 127, 131) | 1.03 (0.96 to 1.11) | 1.16 (1.07 to 1.26) |
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both the before and after 13vPnC Dose 1 blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| mcg/mL | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Serotype 1: Before 13vPnC Dose 1 (n=78,122,200) | 1.03 (0.72 to 1.48) | 0.82 (0.63 to 1.06) | 0.90 (0.73 to 1.10) |
| Serotype 1: After 13vPnC Dose 1 (n=78,122,200) | 3.78 (2.97 to 4.80) | 4.00 (3.19 to 5.01) | 3.91 (3.32 to 4.61) |
| Serotype 3: Before 13vPnC Dose 1 (n=99,127,226) | 0.83 (0.62 to 1.11) | 0.47 (0.37 to 0.58) | 0.60 (0.50 to 0.72) |
| Serotype 3: After 13vPnC Dose 1 (n=99,127,226) | 1.25 (0.99 to 1.58) | 0.75 (0.62 to 0.92) | 0.94 (0.81 to 1.09) |
| Serotype 4: Before 13vPnC Dose 1 (n=95,127,222) | 0.19 (0.14 to 0.25) | 0.35 (0.28 to 0.45) | 0.27 (0.22 to 0.33) |
| Serotype 4: After 13vPnC Dose 1 (n=95,127,222) | 2.62 (1.97 to 3.50) | 2.91 (2.26 to 3.75) | 2.79 (2.31 to 3.36) |
| Serotype 5: Before 13vPnC Dose 1 (n=122,137,259) | 4.18 (3.42 to 5.12) | 3.38 (2.84 to 4.02) | 3.74 (3.28 to 4.27) |
| Serotype 5: After 13vPnC Dose 1 (n=122,137,259) | 4.81 (3.98 to 5.80) | 5.53 (4.63 to 6.61) | 5.18 (4.55 to 5.89) |
| Serotype 6A: Before 13vPnC Dose 1 (n=99,136,235) | 6.22 (5.19 to 7.45) | 2.67 (2.24 to 3.18) | 3.81 (3.32 to 4.37) |
| Serotype 6A: After 13vPnC Dose 1 (n=99,136,235) | 7.31 (6.07 to 8.79) | 6.77 (5.38 to 8.51) | 6.99 (6.00 to 8.15) |
| Serotype 6B: Before 13vPnC Dose 1 (n=131,134,265) | 5.52 (4.59 to 6.64) | 3.23 (2.69 to 3.88) | 4.21 (3.69 to 4.81) |
| Serotype 6B: After 13vPnC Dose 1 (n=131,134,265) | 10.26 (8.37 to 12.58) | 7.29 (5.81 to 9.15) | 8.63 (7.41 to 10.06) |
| Serotype 7F: Before 13vPnC Dose 1 (n=111,134,245) | 0.85 (0.63 to 1.14) | 1.14 (0.94 to 1.37) | 1.00 (0.84 to 1.18) |
| Serotype 7F: After 13vPnC Dose 1 (n=111,134,245) | 4.34 (3.68 to 5.11) | 5.57 (4.57 to 6.78) | 4.97 (4.36 to 5.67) |
| Serotype 9V: Before 13vPnC Dose 1 (n=129,137,266) | 2.10 (1.74 to 2.54) | 1.56 (1.30 to 1.86) | 1.80 (1.58 to 2.05) |
| Serotype 9V: After 13vPnC Dose 1 (n=129,137,266) | 4.77 (4.08 to 5.57) | 5.16 (4.24 to 6.27) | 4.97 (4.38 to 5.63) |
| Serotype 14: Before 13vPnC Dose 1 (n=113,136,249) | 0.76 (0.57 to 1.03) | 2.45 (1.94 to 3.09) | 1.44 (1.18 to 1.76) |
| Serotype 14: After 13vPnC Dose 1 (n=113,136,249) | 12.04 (8.48 to 17.10) | 16.46 (12.38 to 21.90) | 14.28 (11.44 to 17.84) |
| Serotype 18C: Before 13vPnC Dose 1 (n=127,134,261) | 0.66 (0.52 to 0.85) | 0.85 (0.69 to 1.04) | 0.75 (0.64 to 0.88) |
| Serotype 18C: After 13vPnC Dose 1 (n=127,134,261) | 3.92 (3.14 to 4.91) | 5.55 (4.51 to 6.84) | 4.69 (4.02 to 5.46) |
| Serotype 19A: Before 13vPnC Dose 1 (n=133,137,270) | 7.51 (6.34 to 8.90) | 4.78 (4.04 to 5.66) | 5.97 (5.29 to 6.74) |
| Serotype 19A: After 13vPnC Dose 1 (n=133,137,270) | 13.28 (11.11 to 15.87) | 13.03 (10.75 to 15.80) | 13.15 (11.54 to 14.99) |
| Serotype 19F: Before 13vPnC Dose 1 (n=93,126,219) | 1.36 (1.06 to 1.75) | 1.36 (1.07 to 1.73) | 1.36 (1.14 to 1.62) |
| Serotype 19F: After 13vPnC Dose 1 (n=93,126,219) | 4.62 (3.55 to 6.02) | 4.98 (3.74 to 6.62) | 4.82 (3.96 to 5.88) |
| Serotype 23F: Before 13vPnC Dose 1 (n=126,137,263) | 2.29 (1.83 to 2.86) | 1.61 (1.31 to 1.96) | 1.90 (1.64 to 2.21) |
| Serotype 23F: After 13vPnC Dose 1 (n=126,137,263) | 5.65 (4.66 to 6.86) | 5.30 (4.16 to 6.75) | 5.47 (4.68 to 6.39) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose and after 13vPnC Dose 1 blood draws.
| fold rise | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Serotype 1 (n = 78, 122, 200) | 3.67 (2.70 to 4.99) | 4.88 (3.87 to 6.15) | 4.37 (3.63 to 5.25) |
| Serotype 3 (n = 99, 127, 226) | 1.51 (1.27 to 1.79) | 1.62 (1.43 to 1.83) | 1.57 (1.42 to 1.74) |
| Serotype 4 (n = 95, 127, 222) | 14.02 (10.55 to 18.62) | 8.29 (6.55 to 10.49) | 10.38 (8.64 to 12.47) |
| Serotype 5 (n = 122, 137, 259) | 1.15 (1.06 to 1.25) | 1.64 (1.44 to 1.85) | 1.38 (1.28 to 1.50) |
| Serotype 6A (n = 99, 136, 235) | 1.18 (1.02 to 1.35) | 2.54 (2.09 to 3.07) | 1.83 (1.60 to 2.10) |
| Serotype 6B (n = 131, 134, 265) | 1.86 (1.55 to 2.22) | 2.26 (1.87 to 2.72) | 2.05 (1.80 to 2.33) |
| Serotype 7F (n = 111, 134, 245) | 5.11 (3.92 to 6.65) | 4.90 (3.99 to 6.03) | 4.99 (4.24 to 5.88) |
| Serotype 9V (n = 129, 137, 266) | 2.27 (1.97 to 2.61) | 3.32 (2.76 to 3.99) | 2.76 (2.45 to 3.10) |
| Serotype 14 (n = 113, 136, 249) | 15.79 (11.84 to 21.05) | 6.73 (5.17 to 8.76) | 9.91 (8.11 to 12.11) |
| Serotype 18C (n = 127, 134, 261) | 5.92 (4.64 to 7.55) | 6.55 (5.23 to 8.20) | 6.23 (5.29 to 7.35) |
| Serotype 19A (n = 133, 137, 270) | 1.77 (1.55 to 2.02) | 2.73 (2.31 to 3.21) | 2.20 (1.98 to 2.45) |
| Serotype 19F (n = 93, 126, 219) | 3.39 (2.71 to 4.25) | 3.66 (2.96 to 4.52) | 3.54 (3.04 to 4.13) |
| Serotype 23F (n = 126, 137, 263) | 2.47 (2.02 to 3.02) | 3.30 (2.71 to 4.03) | 2.87 (2.49 to 3.31) |
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both the before and after 13vPnC Dose 1 blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| titers | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Serotype 1: Before 13vPnC Dose 1 (n=129,127,256) | 5 (4.3 to 5.8) | 5 (4.3 to 5.2) | 5 (4.4 to 5.3) |
| Serotype 1: After 13vPnC Dose 1 (n=129,127,256) | 49 (35.3 to 68.1) | 57 (41.6 to 79.3) | 53 (42.2 to 66.7) |
| Serotype 3: Before 13vPnC Dose 1 (n=126,128,254) | 8 (6.6 to 10.8) | 5 (4.5 to 5.8) | 7 (5.7 to 7.5) |
| Serotype 3: After 13vPnC Dose 1 (n=126,128,254) | 41 (31.7 to 52.6) | 21 (16.3 to 27.1) | 29 (24.3 to 35.1) |
| Serotype 4: Before 13vPnC Dose 1 (n=108,119,227) | 25 (15.2 to 41.7) | 27 (17.0 to 42.1) | 26 (18.6 to 36.3) |
| Serotype 4: After 13vPnC Dose 1 (n=108,119,227) | 2247 (1611.9 to 3131.4) | 1372 (958.8 to 1963.7) | 1735 (1356.9 to 2218.3) |
| Serotype 5: Before 13vPnC Dose 1 (n=125,122,247) | 5 (4.5 to 6.7) | 6 (4.8 to 6.8) | 6 (4.9 to 6.4) |
| Serotype 5: After 13vPnC Dose 1 (n=125,122,247) | 79 (52.5 to 118.0) | 123 (81.8 to 186.3) | 98 (73.7 to 131.1) |
| Serotype 6A: Before 13vPnC Dose 1 (n=99,98,197) | 157 (84.4 to 292.5) | 61 (35.1 to 106.8) | 98 (64.6 to 149.4) |
| Serotype 6A: After 13vPnC Dose 1 (n=99,98,197) | 3480 (2460.1 to 4921.8) | 1543 (984.4 to 2418.5) | 2322 (1743.1 to 3092.9) |
| Serotype 6B: Before 13vPnC Dose 1 (n=101,120,221) | 279 (155.5 to 501.1) | 231 (143.4 to 372.5) | 252 (174.1 to 364.6) |
| Serotype 6B: After 13vPnC Dose 1 (n=101,120,221) | 3852 (2888.3 to 5137.8) | 2099 (1455.6 to 3028.2) | 2771 (2179.2 to 3522.5) |
| Serotype 7F: Before 13vPnC Dose 1 (n=110,113,223) | 416 (253.5 to 682.9) | 38 (22.9 to 64.6) | 124 (84.3 to 183.8) |
| Serotype 7F: After 13vPnC Dose 1 (n=110,113,223) | 3775 (3019.4 to 4720.1) | 2005 (1443.9 to 2783.1) | 2739 (2237.5 to 3353.5) |
| Serotype 9V: Before 13vPnC Dose 1 (n=109,117,226) | 152 (87.2 to 266.2) | 69 (40.7 to 117.2) | 101 (68.8 to 148.6) |
| Serotype 9V: After 13vPnC Dose 1 (n=109,117,226) | 2533 (1822.7 to 3520.3) | 1231 (836.1 to 1812.2) | 1743 (1347.0 to 2256.4) |
| Serotype 14: Before 13vPnC Dose 1 (n=107,126,233) | 328 (201.4 to 535.5) | 123 (79.6 to 191.4) | 193 (139.0 to 269.2) |
| Serotype 14: After 13vPnC Dose 1 (n=107,126,233) | 3571 (2772.2 to 4600.1) | 1277 (944.9 to 1725.8) | 2048 (1660.8 to 2524.9) |
| Serotype 18C: Before 13vPnC Dose 1 (n=95,120,215) | 42 (21.9 to 79.0) | 25 (15.5 to 39.6) | 31 (21.2 to 45.8) |
| Serotype 18C: After 13vPnC Dose 1 (n=95,120,215) | 2821 (1891.1 to 4208.9) | 1031 (671.3 to 1584.6) | 1609 (1188.2 to 2178.5) |
| Serotype 19A: Before 13vPnC Dose 1 (n=129,128,257) | 28 (19.1 to 40.8) | 23 (16.7 to 32.7) | 26 (19.9 to 32.9) |
| Serotype 19A: After 13vPnC Dose 1 (n=129,128,257) | 506 (381.9 to 671.7) | 390 (275.2 to 552.8) | 445 (355.7 to 555.9) |
| Serotype 19F: Before 13vPnC Dose 1 (n=123,123,246) | 11 (7.6 to 15.5) | 14 (9.5 to 20.1) | 12 (9.5 to 15.8) |
| Serotype 19F: After 13vPnC Dose 1 (n=123,123,246) | 425 (285.3 to 632.5) | 214 (130.4 to 352.3) | 302 (219.3 to 415.2) |
| Serotype 23F: Before 13vPnC Dose 1 (n=118,125,243) | 14 (9.3 to 22.0) | 7 (5.3 to 9.0) | 10 (7.6 to 12.7) |
| Serotype 23F: After 13vPnC Dose 1 (n=118,125,243) | 587 (379.3 to 907.7) | 140 (86.6 to 227.6) | 281 (200.8 to 393.7) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose and after 13vPnC Dose 1 blood draws.
| fold rise | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Serotype 1 (n = 129, 127, 256) | 9.8 (6.97 to 13.81) | 12.2 (8.84 to 16.84) | 10.9 (8.65 to 13.81) |
| Serotype 3 (n = 126, 128, 254) | 4.8 (3.72 to 6.30) | 4.1 (3.22 to 5.30) | 4.5 (3.73 to 5.35) |
| Serotype 4 (n = 108, 119, 227) | 89.4 (51.43 to 155.31) | 51.3 (31.16 to 84.59) | 66.8 (46.17 to 96.75) |
| Serotype 5 (n = 125, 122, 247) | 14.4 (9.56 to 21.67) | 21.7 (14.55 to 32.32) | 17.6 (13.25 to 23.44) |
| Serotype 6A (n = 99, 98, 197) | 22.2 (12.61 to 38.90) | 25.2 (14.51 to 43.83) | 23.6 (15.98 to 34.94) |
| Serotype 6B (n = 101, 120, 221) | 13.8 (8.12 to 23.45) | 9.1 (5.91 to 13.95) | 11.0 (7.87 to 15.37) |
| Serotype 7F (n = 110, 113, 223) | 9.1 (5.79 to 14.23) | 52.2 (31.42 to 86.57) | 22.0 (15.42 to 31.42) |
| Serotype 9V (n = 109, 117, 226) | 16.6 (9.71 to 28.47) | 17.8 (10.53 to 30.18) | 17.2 (11.87 to 25.04) |
| Serotype 14 (n = 107, 126, 233) | 10.9 (6.79 to 17.41) | 10.3 (6.82 to 15.70) | 10.6 (7.76 to 14.44) |
| Serotype 18C (n = 95, 120, 215) | 67.9 (35.25 to 130.73) | 41.6 (24.59 to 70.26) | 51.6 (34.27 to 77.78) |
| Serotype 19A (n = 129, 128, 257) | 18.1 (12.52 to 26.25) | 16.7 (11.78 to 23.61) | 17.4 (13.51 to 22.38) |
| Serotype 19F (n = 123, 123, 246) | 39.0 (24.56 to 62.05) | 15.5 (9.77 to 24.65) | 24.6 (17.69 to 34.25) |
| Serotype 23F (n = 118, 125, 243) | 41.1 (24.94 to 67.81) | 20.2 (12.78 to 32.05) | 28.6 (20.34 to 40.10) |
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both after 13vPnC Dose 3 and after 23vPS Dose blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| mcg/mL | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Serotype 1: After 13vPnC Dose 3 (n=128,127,255) | 4.08 (3.53 to 4.73) | 3.94 (3.22 to 4.82) | 4.01 (3.54 to 4.54) |
| Serotype 1: After 23vPS Dose (n=128,127,255) | 4.42 (3.80 to 5.14) | 4.02 (3.32 to 4.85) | 4.21 (3.74 to 4.75) |
| Serotype 3: After 13vPnC Dose 3 (n=124,118,242) | 1.49 (1.27 to 1.75) | 1.04 (0.87 to 1.26) | 1.25 (1.11 to 1.42) |
| Serotype 3: After 23vPS Dose (n=124,118,242) | 1.65 (1.42 to 1.92) | 0.98 (0.82 to 1.17) | 1.28 (1.14 to 1.44) |
| Serotype 4: After 13vPnC Dose 3 (n=133,128,261) | 3.29 (2.79 to 3.87) | 3.19 (2.59 to 3.93) | 3.24 (2.84 to 3.70) |
| Serotype 4: After 23vPS Dose (n=133,128,261) | 3.28 (2.77 to 3.88) | 3.01 (2.44 to 3.72) | 3.15 (2.75 to 3.59) |
| Serotype 5: After 13vPnC Dose 3 (n=132,130,262) | 4.73 (4.02 to 5.57) | 5.54 (4.64 to 6.63) | 5.12 (4.54 to 5.78) |
| Serotype 5: After 23vPS Dose (n=132,130,262) | 5.08 (4.33 to 5.95) | 6.20 (5.23 to 7.35) | 5.61 (4.99 to 6.30) |
| Serotype 6A: After 13vPnC Dose 3 (n=122,129,251) | 8.20 (6.99 to 9.61) | 7.07 (5.75 to 8.69) | 7.60 (6.67 to 8.66) |
| Serotype 6A: After 23vPS Dose (n=122,129,251) | 7.98 (6.85 to 9.31) | 6.71 (5.51 to 8.17) | 7.30 (6.44 to 8.27) |
| Serotype 6B: After 13vPnC Dose 3 (n=133,129,262) | 12.25 (10.31 to 14.55) | 8.29 (6.78 to 10.13) | 10.10 (8.84 to 11.55) |
| Serotype 6B: After 23vPS Dose (n=133,129,262) | 11.10 (9.39 to 13.13) | 8.25 (6.80 to 10.01) | 9.59 (8.44 to 10.90) |
| Serotype 7F: After 13vPnC Dose 3 (n=133,130,263) | 5.05 (4.39 to 5.81) | 5.88 (4.93 to 7.02) | 5.44 (4.87 to 6.09) |
| Serotype 7F: After 23vPS Dose (n=133,130,263) | 5.15 (4.50 to 5.90) | 5.93 (5.02 to 7.00) | 5.52 (4.96 to 6.14) |
| Serotype 9V: After 13vPnC Dose 3 (n=133,130,263) | 5.02 (4.40 to 5.72) | 5.49 (4.59 to 6.57) | 5.25 (4.70 to 5.86) |
| Serotype 9V: After 23vPS Dose (n=133,130,263) | 5.27 (4.62 to 6.00) | 5.83 (4.88 to 6.96) | 5.54 (4.96 to 6.18) |
| Serotype 14: After 13vPnC Dose 3 (n=133,130,263) | 13.18 (10.19 to 17.05) | 15.35 (11.97 to 19.69) | 14.21 (11.89 to 16.98) |
| Serotype 14: After 23vPS Dose (n=133,130,263) | 12.98 (10.10 to 16.67) | 16.24 (12.82 to 20.57) | 14.50 (12.21 to 17.21) |
| Serotype 18C: After 13vPnC Dose 3 (n=132,130,262) | 3.84 (3.21 to 4.59) | 5.17 (4.25 to 6.28) | 4.45 (3.90 to 5.08) |
| Serotype 18C: After 23vPS Dose (n=132,130,262) | 3.54 (2.98 to 4.20) | 4.80 (3.98 to 5.79) | 4.12 (3.62 to 4.68) |
| Serotype 19A: After 13vPnC Dose 3 (n=133,130,263) | 14.16 (12.21 to 16.41) | 13.21 (11.13 to 15.68) | 13.68 (12.22 to 15.31) |
| Serotype 19A: After 23vPS Dose (n=133,130,263) | 13.16 (11.31 to 15.33) | 13.28 (11.24 to 15.69) | 13.22 (11.82 to 14.79) |
| Serotype 19F: After 13vPnC Dose 3 (n=130,127,257) | 6.15 (5.09 to 7.45) | 5.67 (4.47 to 7.19) | 5.91 (5.08 to 6.87) |
| Serotype 19F: After 23vPS Dose (n=130,127,257) | 6.78 (5.65 to 8.14) | 5.84 (4.62 to 7.39) | 6.30 (5.44 to 7.30) |
| Serotype 23F: After 13vPnC Dose 3 (n=132,129,261) | 6.69 (5.60 to 7.98) | 7.30 (5.87 to 9.09) | 6.98 (6.07 to 8.03) |
| Serotype 23F: After 23vPS Dose (n=132,129,261) | 5.99 (5.05 to 7.11) | 7.03 (5.69 to 8.70) | 6.49 (5.66 to 7.43) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 23vPS Dose were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 3 and 1 month after 23vPS Dose blood draws.
| fold rise | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Serotype 1 (n = 128, 127, 255) | 1.08 (1.01 to 1.16) | 1.02 (0.96 to 1.08) | 1.05 (1.00 to 1.10) |
| Serotype 3 (n = 124, 118, 242) | 1.11 (1.03 to 1.20) | 0.94 (0.88 to 1.00) | 1.02 (0.97 to 1.08) |
| Serotype 4 (n = 133, 128, 261) | 1.00 (0.94 to 1.05) | 0.94 (0.90 to 0.99) | 0.97 (0.94 to 1.01) |
| Serotype 5 (n = 132, 130, 262) | 1.07 (1.02 to 1.13) | 1.12 (1.05 to 1.19) | 1.09 (1.05 to 1.14) |
| Serotype 6A (n = 122, 129, 251) | 0.97 (0.92 to 1.04) | 0.95 (0.91 to 0.99) | 0.96 (0.93 to 1.00) |
| Serotype 6B (n = 133, 129, 262) | 0.91 (0.87 to 0.95) | 1.00 (0.96 to 1.04) | 0.95 (0.92 to 0.98) |
| Serotype 7F (n = 133, 130, 263) | 1.02 (0.97 to 1.07) | 1.01 (0.95 to 1.06) | 1.01 (0.98 to 1.05) |
| Serotype 9V (n = 133, 130, 263) | 1.05 (1.00 to 1.10) | 1.06 (1.01 to 1.11) | 1.06 (1.02 to 1.09) |
| Serotype 14 (n = 133, 130, 263) | 0.98 (0.91 to 1.06) | 1.06 (0.99 to 1.13) | 1.02 (0.97 to 1.07) |
| Serotype 18C (n = 132, 130, 262) | 0.92 (0.88 to 0.96) | 0.93 (0.89 to 0.97) | 0.92 (0.90 to 0.95) |
| Serotype 19A (n = 133, 130, 263) | 0.93 (0.89 to 0.97) | 1.01 (0.96 to 1.05) | 0.97 (0.94 to 1.00) |
| Serotype 19F (n = 130, 127, 257) | 1.10 (1.04 to 1.17) | 1.03 (0.97 to 1.09) | 1.07 (1.02 to 1.11) |
| Serotype 23F (n = 132, 129, 261) | 0.90 (0.86 to 0.94) | 0.96 (0.91 to 1.02) | 0.93 (0.89 to 0.96) |
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a mcOPA assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both after 13vPnC Dose 3 and after 23vPS Dose blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| titers | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Serotype 1: After 13vPnC Dose 3 (n=131,125,256) | 70 (53.4 to 93.0) | 67 (50.2 to 90.6) | 69 (56.4 to 84.3) |
| Serotype 1: After 23vPS Dose (n=131,125,256) | 100 (76.6 to 130.3) | 66 (49.0 to 90.2) | 82 (66.9 to 100.2) |
| Serotype 3: After 13vPnC Dose 3 (n=132,128,260) | 114 (94.6 to 136.7) | 78 (61.3 to 98.7) | 94 (81.1 to 109.7) |
| Serotype 3: After 23vPS Dose (n=132,128,260) | 148 (123.9 to 177.3) | 103 (81.6 to 130.9) | 124 (107.0 to 144.0) |
| Serotype 4: After 13vPnC Dose 3 (n=127,126,253) | 3213 (2698.5 to 3826.6) | 1888 (1427.3 to 2498.1) | 2466 (2087.0 to 2913.5) |
| Serotype 4: After 23vPS Dose (n=127,126,253) | 3553 (2984.9 to 4229.7) | 1831 (1366.0 to 2453.7) | 2554 (2146.3 to 3038.7) |
| Serotype 5: After 13vPnC Dose 3 (n=129,124,253) | 270 (197.0 to 370.1) | 143 (97.5 to 209.6) | 198 (154.2 to 253.5) |
| Serotype 5: After 23vPS Dose (n=129,124,253) | 378 (276.5 to 516.9) | 186 (130.9 to 264.4) | 267 (210.6 to 338.6) |
| Serotype 6A: After 13vPnC Dose 3 (n=132,127,259) | 8011 (6580.0 to 9752.1) | 2956 (2240.1 to 3900.3) | 4913 (4109.7 to 5873.6) |
| Serotype 6A: After 23vPS Dose (n=132,127,259) | 7236 (5936.2 to 8819.4) | 2707 (2060.8 to 3556.3) | 4468 (3743.3 to 5333.1) |
| Serotype 6B: After 13vPnC Dose 3 (n=130,126,256) | 7102 (5853.9 to 8615.8) | 3666 (2720.7 to 4940.5) | 5129 (4283.9 to 6141.0) |
| Serotype 6B: After 23vPS Dose (n=130,126,256) | 6652 (5460.8 to 8102.8) | 3324 (2496.6 to 4426.2) | 4728 (3961.1 to 5643.2) |
| Serotype 7F: After 13vPnC Dose 3 (n=131,125,256) | 4640 (3915.9 to 5497.9) | 2821 (2283.2 to 3484.4) | 3639 (3171.6 to 4174.8) |
| Serotype 7F: After 23vPS Dose (n=131,125,256) | 5260 (4470.4 to 6189.9) | 3027 (2455.7 to 3731.3) | 4016 (3508.3 to 4597.9) |
| Serotype 9V: After 13vPnC Dose 3 (n=127,125,252) | 4501 (3606.4 to 5618.0) | 1980 (1394.6 to 2811.7) | 2995 (2424.2 to 3700.8) |
| Serotype 9V: After 23vPS Dose (n=127,125,252) | 5114 (4090.6 to 6393.0) | 2037 (1452.6 to 2857.6) | 3240 (2629.5 to 3991.2) |
| Serotype 14: After 13vPnC Dose 3 (n=127,126,253) | 4023 (3317.5 to 4879.5) | 1431 (1115.7 to 1836.1) | 2405 (2030.8 to 2847.1) |
| Serotype 14: After 23vPS Dose (n=127,126,253) | 4718 (3861.6 to 5764.9) | 1620 (1284.5 to 2043.0) | 2771 (2346.9 to 3270.7) |
| Serotype 18C: After 13vPnC Dose 3 (n=129,121,250) | 5455 (4401.5 to 6761.4) | 1667 (1172.5 to 2370.8) | 3074 (2479.2 to 3810.5) |
| Serotype 18C: After 23vPS Dose (n=129,121,250) | 6468 (5341.1 to 7832.2) | 1835 (1328.1 to 2535.5) | 3515 (2878.5 to 4292.8) |
| Serotype 19A: After 13vPnC Dose 3 (n=131,125,256) | 1021 (837.5 to 1245.6) | 603 (456.7 to 796.3) | 790 (665.2 to 937.4) |
| Serotype 19A: After 23vPS Dose (n=131,125,256) | 1244 (1012.1 to 1529.5) | 691 (531.0 to 898.6) | 933 (788.2 to 1105.5) |
| Serotype 19F: After 13vPnC Dose 3 (n=126,117,243) | 1166 (884.3 to 1537.7) | 564 (375.0 to 848.1) | 822 (642.8 to 1051.0) |
| Serotype 19F: After 23vPS Dose (n=126,117,243) | 1696 (1296.5 to 2217.5) | 790 (547.5 to 1139.7) | 1174 (934.2 to 1474.8) |
| Serotype 23F: After 13vPnC Dose 3 (n=128,126,254) | 2346 (1883.3 to 2922.6) | 650 (435.3 to 969.9) | 1241 (976.6 to 1576.7) |
| Serotype 23F: After 23vPS Dose (n=128,126,254) | 2595 (2143.3 to 3141.5) | 580 (386.1 to 871.8) | 1234 (970.1 to 1570.3) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 23vPS Dose were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 3 and 1 month after 23vPS Dose blood draws.
| fold rise | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Serotype 1 (n = 131, 125, 256) | 1.4 (1.23 to 1.63) | 1.0 (0.86 to 1.13) | 1.2 (1.08 to 1.31) |
| Serotype 3 (n = 132, 128, 260) | 1.3 (1.15 to 1.48) | 1.3 (1.17 to 1.51) | 1.3 (1.20 to 1.44) |
| Serotype 4 (n = 127, 126, 253) | 1.1 (1.04 to 1.18) | 1.0 (0.87 to 1.09) | 1.0 (0.97 to 1.10) |
| Serotype 5 (n = 129, 124, 253) | 1.4 (1.15 to 1.71) | 1.3 (1.13 to 1.50) | 1.4 (1.20 to 1.53) |
| Serotype 6A (n = 132, 127, 259) | 0.9 (0.85 to 0.96) | 0.9 (0.86 to 0.97) | 0.9 (0.87 to 0.95) |
| Serotype 6B (n = 130, 126, 256) | 0.9 (0.87 to 1.01) | 0.9 (0.79 to 1.04) | 0.9 (0.86 to 0.99) |
| Serotype 7F (n = 131, 125, 256) | 1.1 (1.06 to 1.21) | 1.1 (0.93 to 1.23) | 1.1 (1.02 to 1.19) |
| Serotype 9V (n = 127, 125, 252) | 1.1 (1.05 to 1.23) | 1.0 (0.84 to 1.27) | 1.1 (0.97 to 1.21) |
| Serotype 14 (n = 127, 126, 253) | 1.2 (1.07 to 1.28) | 1.1 (1.03 to 1.24) | 1.2 (1.08 to 1.23) |
| Serotype 18C (n = 129, 121, 250) | 1.2 (1.04 to 1.35) | 1.1 (0.92 to 1.31) | 1.1 (1.03 to 1.27) |
| Serotype 19A (n = 131, 125, 256) | 1.2 (1.11 to 1.34) | 1.1 (1.03 to 1.27) | 1.2 (1.10 to 1.27) |
| Serotype 19F (n = 126, 117, 243) | 1.5 (1.25 to 1.69) | 1.4 (1.14 to 1.72) | 1.4 (1.26 to 1.62) |
| Serotype 23F (n = 128, 126, 254) | 1.1 (0.96 to 1.28) | 0.9 (0.81 to 0.98) | 1.0 (0.91 to 1.09) |
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters (cm) for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged greater than (\>) 12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Report of severe swelling was confirmed as data entry error.
| percentage of participants | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Redness: Any (n = 92, 88, 180) | 20.7 | 2.3 | 11.7 |
| Redness: Mild (n = 91, 88, 179) | 19.8 | 2.3 | 11.2 |
| Redness: Moderate (n = 85, 88, 173) | 2.4 | 0.0 | 1.2 |
| Redness: Severe (n = 84, 88, 172) | 0.0 | 0.0 | 0.0 |
| Swelling: Any (n = 97, 94, 191) | 29.9 | 9.6 | 19.9 |
| Swelling: Mild (n = 91, 93, 184) | 17.6 | 8.6 | 13.0 |
| Swelling: Moderate (n = 92, 89, 181) | 16.3 | 1.1 | 8.8 |
| Swelling: Severe (n = 84, 88, 172) | 1.2 | 0.0 | 0.6 |
| Pain at Injection Site: Any (n = 117, 121, 238) | 68.4 | 62.8 | 65.5 |
| Pain at Injection Site: Mild (n = 112, 116, 228) | 55.4 | 56.0 | 55.7 |
| Pain at Injection Site: Moderate (n = 94, 94, 188) | 28.7 | 18.1 | 23.4 |
| Pain at Injection Site: Severe (n = 86, 89, 175) | 8.1 | 2.2 | 5.1 |
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 cm for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged \>12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).
| percentage of participants | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Redness: Any (n = 101, 86, 187) | 13.9 | 2.3 | 8.6 |
| Redness: Mild (n = 100, 86, 186) | 10.0 | 2.3 | 6.5 |
| Redness: Moderate (n = 95, 85, 180) | 4.2 | 0.0 | 2.2 |
| Redness: Severe (n = 93, 85, 178) | 1.1 | 0.0 | 0.6 |
| Swelling: Any (n = 103, 88, 191) | 25.2 | 8.0 | 17.3 |
| Swelling: Mild (n = 102, 88, 190) | 18.6 | 8.0 | 13.7 |
| Swelling: Moderate (n = 99, 85, 184) | 12.1 | 0.0 | 6.5 |
| Swelling: Severe (n = 93, 85, 178) | 0.0 | 0.0 | 0.0 |
| Pain at Injection Site: Any (n = 117, 119, 236) | 60.7 | 79.8 | 70.3 |
| Pain at Injection Site: Mild (n = 110, 117, 227) | 49.1 | 72.6 | 61.2 |
| Pain at Injection Site: Moderate (n= 103, 96, 199) | 24.3 | 27.1 | 25.6 |
| Pain at Injection Site: Severe (n = 93, 86, 179) | 5.4 | 3.5 | 4.5 |
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 cm for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged \>12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).
| percentage of participants | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Redness: Any (n = 84, 70, 154) | 8.3 | 0.0 | 4.5 |
| Redness: Mild (n = 83, 70, 153) | 7.2 | 0.0 | 3.9 |
| Redness: Moderate (n = 82, 70, 152) | 2.4 | 0.0 | 1.3 |
| Redness: Severe (n = 80, 70, 150) | 0.0 | 0.0 | 0.0 |
| Swelling: Any (n = 89, 71, 160) | 18.0 | 4.2 | 11.9 |
| Swelling: Mild (n = 86, 71, 157) | 10.5 | 4.2 | 7.6 |
| Swelling: Moderate (n = 84, 70, 154) | 9.5 | 0.0 | 5.2 |
| Swelling: Severe (n = 80, 70, 150) | 0.0 | 0.0 | 0.0 |
| Pain at Injection Site: Any (n = 104, 109, 213) | 52.9 | 69.7 | 61.5 |
| Pain at Injection Site: Mild (n = 96, 105, 201) | 41.7 | 63.8 | 53.2 |
| Pain at Injection Site: Moderate (n = 89, 78, 167) | 19.1 | 24.4 | 21.6 |
| Pain at Injection Site: Severe (n = 83, 73, 156) | 4.8 | 5.5 | 5.1 |
Specific systemic events (fever \>=38 degrees Celsius\[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours). All reporting of fever \>40 degrees C except 2 participants and all reporting of severe vomiting, after 13vPnC Dose 1, were confirmed as data entry errors.
| percentage of participants | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Fever: >=38 degrees C (n= 94, 95, 189) | 19.1 | 17.9 | 18.5 |
| Fever: >=38, <38.5 degrees C (n = 87, 92, 179) | 8.0 | 8.7 | 8.4 |
| Fever: >=38.5, <39 degrees C (n = 85, 89, 174) | 2.4 | 3.4 | 2.9 |
| Fever: >=39, =<40 degrees C (n = 86, 88, 174) | 4.7 | 2.3 | 3.4 |
| Fever: >40 degrees C (n = 88, 93, 181) | 6.8 | 8.6 | 7.7 |
| Fatigue: Any (n = 111, 119, 230) | 47.7 | 58.8 | 53.5 |
| Fatigue: Mild (n = 105, 113, 218) | 33.3 | 51.3 | 42.7 |
| Fatigue: Moderate (n = 96, 99, 195) | 26.0 | 28.3 | 27.2 |
| Fatigue: Severe (n = 86, 92, 178) | 9.3 | 8.7 | 9.0 |
| Headache: Any (n = 107, 113, 220) | 39.3 | 61.1 | 50.5 |
| Headache: Mild (n = 100, 109, 209) | 33.0 | 57.8 | 45.9 |
| Headache: Moderate (n = 94, 97, 191) | 18.1 | 22.7 | 20.4 |
| Headache: Severe (n = 87, 89, 176) | 6.9 | 9.0 | 8.0 |
| Vomiting: Any (n = 89, 91, 180) | 18.0 | 7.7 | 12.8 |
| Vomiting: Mild (n = 89, 91, 180) | 14.6 | 7.7 | 11.1 |
| Vomiting: Moderate (n = 84, 88, 172) | 2.4 | 0.0 | 1.2 |
| Vomiting: Severe (n = 85, 88, 173) | 2.4 | 0.0 | 1.2 |
| Diarrhea: Any (n = 94, 105, 199) | 25.5 | 34.3 | 30.2 |
| Diarrhea: Mild (n = 92, 104, 196) | 19.6 | 29.8 | 25.0 |
| Diarrhea: Moderate (n = 86, 91, 177) | 8.1 | 7.7 | 7.9 |
| Diarrhea: Severe (n = 85, 88, 173) | 1.2 | 1.1 | 1.2 |
| Muscle Pain: Any (n = 108, 118, 226) | 48.1 | 62.7 | 55.8 |
| Muscle Pain: Mild (n = 103, 110, 213) | 36.9 | 56.4 | 46.9 |
| Muscle Pain: Moderate (n = 89, 98, 187) | 19.1 | 19.4 | 19.3 |
| Muscle Pain: Severe (n = 86, 91, 177) | 5.8 | 5.5 | 5.6 |
| Joint Pain: Any (n = 100, 105, 205) | 34.0 | 42.9 | 38.5 |
| Joint Pain: Mild (n = 98, 101, 199) | 26.5 | 36.6 | 31.7 |
| Joint Pain: Moderate (n = 89, 95, 184) | 12.4 | 17.9 | 15.2 |
| Joint Pain: Severe (n = 84, 91, 175) | 4.8 | 4.4 | 4.6 |
| Use of Medication to Treat Pain (n = 101, 96, 197) | 33.7 | 24.0 | 28.9 |
| Use of Medication to Treat Fever (n=112, 107, 219) | 44.6 | 39.3 | 42.0 |
Specific systemic events (fever \>=38 degrees Celsius\[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours). All reporting of fever \>40 degrees C and all reporting of severe vomiting, after 13vPnC Dose 2, were confirmed as data entry errors.
| percentage of participants | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Fever: >=38 degrees C (n= 102, 88, 190) | 16.7 | 11.4 | 14.2 |
| Fever: >=38, <38.5 degrees C (n = 96, 87, 183) | 7.3 | 9.2 | 8.2 |
| Fever: >=38.5, <39 degrees C (n = 98, 85, 183) | 6.1 | 1.2 | 3.8 |
| Fever: >=39, =<40 degrees C (n = 97, 87, 184) | 7.2 | 3.4 | 5.4 |
| Fever: >40 degrees C (n = 95, 85, 180) | 1.1 | 1.2 | 1.1 |
| Fatigue: Any (n = 106, 105, 211) | 33.0 | 48.6 | 40.8 |
| Fatigue: Mild (n = 104, 103, 207) | 24.0 | 42.7 | 33.3 |
| Fatigue: Moderate (n = 96, 88, 184) | 10.4 | 21.6 | 15.8 |
| Fatigue: Severe (n = 95, 88, 183) | 7.4 | 5.7 | 6.6 |
| Headache: Any (n = 101, 106, 207) | 28.7 | 49.1 | 39.1 |
| Headache: Mild (n = 97, 102, 199) | 18.6 | 40.2 | 29.6 |
| Headache: Moderate (n = 97, 93, 190) | 13.4 | 28.0 | 20.5 |
| Headache: Severe (n = 94, 88, 182) | 2.1 | 3.4 | 2.7 |
| Vomiting: Any (n = 96, 89, 185) | 10.4 | 10.1 | 10.3 |
| Vomiting: Mild (n = 94, 89, 183) | 6.4 | 9.0 | 7.7 |
| Vomiting: Moderate (n = 94, 85, 179) | 3.2 | 1.2 | 2.2 |
| Vomiting: Severe (n = 94, 85, 179) | 3.2 | 0.0 | 1.7 |
| Diarrhea: Any (n = 95, 95, 190) | 10.5 | 26.3 | 18.4 |
| Diarrhea: Mild (n = 94, 93, 187) | 7.4 | 24.7 | 16.0 |
| Diarrhea: Moderate (n = 93, 87, 180) | 3.2 | 8.0 | 5.6 |
| Diarrhea: Severe (n = 94, 85, 179) | 4.3 | 1.2 | 2.8 |
| Muscle Pain: Any (n = 112, 104, 216) | 37.5 | 52.9 | 44.9 |
| Muscle Pain: Mild (n = 105, 103, 208) | 25.7 | 46.6 | 36.1 |
| Muscle Pain: Moderate (n = 100, 91, 191) | 15.0 | 20.9 | 17.8 |
| Muscle Pain: Severe (n = 95, 85, 180) | 5.3 | 2.4 | 3.9 |
| Joint Pain: Any (n = 106, 95, 201) | 26.4 | 34.7 | 30.3 |
| Joint Pain: Mild (n = 100, 93, 193) | 16.0 | 29.0 | 22.3 |
| Joint Pain: Moderate (n = 99, 89, 188) | 11.1 | 12.4 | 11.7 |
| Joint Pain: Severe (n = 94, 85, 179) | 4.3 | 2.4 | 3.4 |
| Use of Medication to Treat Pain (n = 100, 91, 191) | 20.0 | 17.6 | 18.8 |
| Use of Medication to Treat Fever (n=102, 96, 198) | 28.4 | 26.0 | 27.3 |
Specific systemic events (fever \>=38 degrees Celsius\[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours). All reporting of fever \>40 degrees C except 1 participant and all reporting of severe vomiting, after 13vPnC Dose 3, were confirmed as data entry errors.
| percentage of participants | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Fever: >=38 degrees C (n= 85, 73, 158) | 10.6 | 11.0 | 10.8 |
| Fever: >=38, <38.5 degrees C (n = 82, 73, 155) | 6.1 | 5.5 | 5.8 |
| Fever: >=38.5, <39 degrees C (n = 81, 72, 153) | 2.5 | 5.6 | 3.9 |
| Fever: >=39, =<40 degrees C (n = 82, 70, 152) | 2.4 | 2.9 | 2.6 |
| Fever: >40 degrees C (n = 83, 70, 153) | 3.6 | 1.4 | 2.6 |
| Fatigue: Any (n = 92, 91, 183) | 25.0 | 47.3 | 36.1 |
| Fatigue: Mild (n = 89, 88, 177) | 20.2 | 39.8 | 29.9 |
| Fatigue: Moderate (n = 83, 80, 163) | 6.0 | 25.0 | 15.3 |
| Fatigue: Severe (n = 83, 73, 156) | 4.8 | 8.2 | 6.4 |
| Headache: Any (n = 88, 89, 177) | 18.2 | 46.1 | 32.2 |
| Headache: Mild (n = 84, 87, 171) | 10.7 | 41.4 | 26.3 |
| Headache: Moderate (n = 83, 77, 160) | 8.4 | 19.5 | 13.8 |
| Headache: Severe (n = 82, 72, 154) | 3.7 | 6.9 | 5.2 |
| Vomiting: Any (n = 85, 74, 159) | 8.2 | 9.5 | 8.8 |
| Vomiting: Mild (n = 84, 72, 156) | 7.1 | 5.6 | 6.4 |
| Vomiting: Moderate (n = 82, 73, 155) | 2.4 | 5.5 | 3.9 |
| Vomiting: Severe (n = 81, 72, 153) | 1.2 | 2.8 | 2.0 |
| Diarrhea: Any (n = 81, 81, 162) | 4.9 | 28.4 | 16.7 |
| Diarrhea: Mild (n = 81, 79, 160) | 4.9 | 25.3 | 15.0 |
| Diarrhea: Moderate (n = 80, 73, 153) | 1.3 | 6.8 | 3.9 |
| Diarrhea: Severe (n = 81, 73, 154) | 1.2 | 4.1 | 2.6 |
| Muscle Pain: Any (n = 99, 92, 191) | 37.4 | 47.8 | 42.4 |
| Muscle Pain: Mild (n = 93, 89, 182) | 25.8 | 37.1 | 31.3 |
| Muscle Pain: Moderate (n = 85, 78, 163) | 12.9 | 24.4 | 18.4 |
| Muscle Pain: Severe (n = 84, 72, 156) | 8.3 | 5.6 | 7.1 |
| Joint Pain: Any (n = 91, 83, 174) | 24.2 | 32.5 | 28.2 |
| Joint Pain: Mild (n = 88, 82, 170) | 15.9 | 28.0 | 21.8 |
| Joint Pain: Moderate (n = 82, 77, 159) | 7.3 | 15.6 | 11.3 |
| Joint Pain: Severe (n = 81, 71, 152) | 2.5 | 2.8 | 2.6 |
| Use of Medication to Treat Pain (n = 90, 79, 169) | 17.8 | 21.5 | 19.5 |
| Use of Medication to Treat Fever (n = 89, 75, 164) | 20.2 | 20.0 | 20.1 |
Collected over Informed consent through 6-month follow-up after 13vPnC Dose 3. Local reactions and systemic events assessed within 14 days after: 13vPnC Dose 1 (Day 1); 13vPnC Dose 2 (28-42 days after 13vPnC Dose 1); and 13vPnC Dose 3 (28-42 days after 13vPnC Dose 2). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prior 13vPnC Dose 1 | — | 1/301 (0.3%) | 16/301 (5.3%) |
| 13vPnC Dose 1 | — | 1/301 (0.3%) | 216/301 (71.8%) |
| 13vPnC Dose 2 | — | 4/290 (1.4%) | 171/290 (59%) |
| 13vPnC Dose 3 | — | 1/286 (0.3%) | 137/286 (47.9%) |
| 23vPS Dose | — | 0/282 (0%) | 31/282 (11%) |
| Follow-up | — | 1/282 (0.4%) | 2/282 (0.7%) |
| Event | Prior 13vPnC Dose 1 | 13vPnC Dose 1 | 13vPnC Dose 2 | 13vPnC Dose 3 | 23vPS Dose | Follow-up |
|---|---|---|---|---|---|---|
| Pharyngitis bacterialInfections and infestations | 0/301 | 0/301 | 1/290 | 0/286 | 0/282 | 1/282 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/301 | 0/301 | 0/290 | 1/286 | 0/282 | 0/282 |
| HaemorrhoidsGastrointestinal disorders | 0/301 | 0/301 | 1/290 | 0/286 | 0/282 | 0/282 |
| Lobar pneumoniaInfections and infestations | 0/301 | 0/301 | 1/290 | 0/286 | 0/282 | 0/282 |
| TonsillitisInfections and infestations | 0/301 | 0/301 | 1/290 | 0/286 | 0/282 | 0/282 |
| ConvulsionNervous system disorders | 0/301 | 1/301 | 0/290 | 0/286 | 0/282 | 0/282 |
| LymphadenopathyBlood and lymphatic system disorders | 1/301 | 0/301 | 0/290 | 0/286 | 0/282 | 0/282 |
| Croup infectiousInfections and infestations | 1/301 | 0/301 | 0/290 | 0/286 | 0/282 | 0/282 |
| Event | Prior 13vPnC Dose 1 | 13vPnC Dose 1 | 13vPnC Dose 2 | 13vPnC Dose 3 | 23vPS Dose | Follow-up |
|---|---|---|---|---|---|---|
| Pain at injection site (Any)Skin and subcutaneous tissue disorders | — | 156/238 | 166/236 | 131/213 | — | — |
| Pain at injection site (Mild)Skin and subcutaneous tissue disorders | — | 127/228 | 139/227 | 107/201 | — | — |
| Muscle pain (Any)General disorders | — | 126/226 | 97/216 | 81/191 | — | — |
| Fatigue (Any)General disorders | — | 123/230 | 86/211 | 66/183 | — | — |
| Headache (Any)General disorders | — | 111/220 | 81/207 | 57/177 | — | — |
| Muscle pain (Mild)General disorders | — | 100/213 | 75/208 | 57/182 | — | — |
| Headache (Mild)General disorders | — | 96/209 | 59/199 | 45/171 | — | — |
| Fatigue (Mild)General disorders | — | 93/218 | 69/207 | 53/177 | — | — |
| Joint pain (Any)General disorders | — | 79/205 | 61/201 | 49/174 | — | — |
| Joint pain (Mild)General disorders | — | 63/199 | 43/193 | 37/170 | — | — |
Safety population included all enrolled participants who received at least 1 dose of investigational product.
| Age, Continuous(years) | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | Total |
|---|---|---|---|
| Mean | 10.3 ± 3.04 | 41.2 ± 8.45 | 25.8 ± 16.72 |
| Sex: Female, Male(Participants) | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | Total |
|---|---|---|---|
| Female | 76 | 88 | 164 |
| Male | 74 | 63 | 137 |
The record gives a start of Mar 2010, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine